Steffensen Charlotte, Mægbæk Merete Lund, Laurberg Peter, Andersen Marianne, Kistorp Caroline, Nørrelund Helene, Dal Jakob, Jørgensen Jens Otto Lunde
Medicinsk Endokrinologisk Afdeling, Aarhus Universitetshospital, Nørrebrogade 44, 8000 Aarhus C.
Ugeskr Laeger. 2014 Jan 6;176(1):58-60.
Treatment with dopamin agonists, particularly cabergoline, is the primary and preferred therapy for prolactinomas and symptomatic hyperprolactinaemia due to its effectiveness and tolerability. However, an association has been demonstrated between fibrotic heart valve disease and high-dose dopamin agonist use in patients with Parkinson's disease in several echocardiographic studies. Such observations have prompted a number of studies of valvular function in cabergoline-treated hyperprolactinaemia patients. These studies have failed to show an increased prevalence of clinically significant valvular regurgitation.
使用多巴胺激动剂，尤其是卡麦角林进行治疗，因其有效性和耐受性，是泌乳素瘤和有症状高泌乳素血症的主要且首选治疗方法。然而，在多项超声心动图研究中，已证实在帕金森病患者中，心脏瓣膜纤维化疾病与高剂量多巴胺激动剂的使用之间存在关联。此类观察结果促使人们对接受卡麦角林治疗的高泌乳素血症患者的瓣膜功能进行了多项研究。这些研究未能显示临床上显著瓣膜反流的患病率增加。
